HPV vaccines: Global perspectives

Prophylactic HPV vaccines.

The HPV L1 VLP vaccines are immensely important developments in public health and the benefits that they promise are immense, offering the opportunity to prevent, in the long term, 80% of cervical cancers, 60% of vulval cancers and 80% of anal cancers in women. In the short to medium term they will prevent at least 90% of genital warts and have a major impact on the incidence of high grade CIN,...

Immunobiology of HPV and HPV vaccines.

Genital human papillomavirus (HPV) infection with both low- and high-risk types is common, but most infections resolve as a result of a cell-mediated immune response. Failure to induce an effective immune response is related to inefficient activation of innate immunity and ineffective priming of the adaptive immune response; this defective immune response facilitates viral persistence, a key fe...

Prophylactic HPV Vaccines

Cervical cancer and its precursor intra-epithelial lesions are linked to infection by a subset of human papillomavirus (HPV) types, the so-called “high-risk” HPVs, the most prevalent being HPV16 and HPV18. Two prophylactic vaccines containing combinations of the major capsid protein (L1) of HPV16 and HPV18 have been shown to efficiently prevent infection by inducing capsid-specific neutralizing...

Human papillomavirus (HPV) vaccines

Kinoshita et al. 2014 48 patients (from same clinic as above and largely overlapping time period). 18 fulfilling the diagnostic criteria for CRPS-1. Abstract /Kinoshita et al, 2014 17 patients from an unknown time period. -Kinoshita et al, 2014 17 patients from an unknown time period. Letter to the editor / 2 adolescents Both patients fulfilled the fibromyalgia criteria and were 22 Richards et ...

HPV vaccines prophylactic, not therapeutic.